Trial in Progress: Phase 1/2 Study of Donor-Derived Anti-CD33 Chimeric Antigen Receptor Expressing T Cells (VCAR33) in Patients with Relapsed or Refractory Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation
Nirali N. Shah(National Institutes of Health), Guenther Koehne(Baptist Hospital of Miami), Divya Koura(University of California San Diego), Muhammad Umair Mushtaq(Health Innovations (United States)), Hyung C. Suh(Science Applications International Corporation (United States)), Rupa Narayan(Stanford University), Lori Muffly(Stanford University), Jacques Azzi(Icahn School of Medicine at Mount Sinai), Brian McClune(University of Minnesota Medical Center), John F. DiPersio(Washington University in St. Louis), Jennifer Whangbo(Boston Children's Hospital), Sritama Nath(University of North Carolina at Charlotte), Abhinav Deol(Wayne State University), John Magenau(University of Michigan)
Cited by 2
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.2k